← Back to Search

Meditation Therapy for Cancer-Related Anxiety and Depression

Waitlist Available
Led By Gabriel Lopez
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Diagnosis of a formal thought disorder (e.g., schizophrenia)
Screening 3 weeks
Treatment Varies
Follow Up up to 2 weeks
Awards & highlights


This trial is testing how well self-administered meditation therapy can help improve anxiety and depression in cancer patients who are experiencing psychosocial distress.

Who is the study for?
This trial is for cancer patients at MD Anderson who are currently in treatment or have finished it, can read and understand English, consent to participate, and can visit the Texas Medical Center. They should feel some anxiety or depression but not be severely affected (scores between 4-11 on ESAS). If they're taking anxiety meds, doses must be stable for six weeks with no changes expected soon.Check my eligibility
What is being tested?
The study is testing if meditation therapy helps reduce anxiety and depression in cancer patients feeling psychosocial distress. It involves self-administered techniques like deep breathing to improve mental well-being and quality of life during or after cancer treatment.See study design
What are the potential side effects?
Meditation therapy generally has minimal side effects; however, participants may experience increased emotional sensitivity or discomfort when confronting difficult feelings during practice.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I have been diagnosed with a thought disorder like schizophrenia.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility of self-administered meditation
Secondary outcome measures
Frequency of meditation and choice of length of meditation
The study will evaluate participant satisfaction with the meditation delivery and tracking program using appropriate descriptive statistics.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group I (meditation)Experimental Treatment3 Interventions
Patients watch a pre-recorded instructional meditation video via an iPod meditation app. Patients then complete meditation exercises using the meditation app over 5-15 minutes QD for up to 2 weeks. Patients also complete questionnaires before and after meditation sessions and participate in an interview over 10 minutes.
Group II: Group II (waitlist control)Active Control3 Interventions
Patients receive supportive care, such as access to social workers, support groups, spiritual care, or other patient services for up to 2 weeks. Patients also complete questionnaires over 15-20 minutes and participate in an interview over 10 minutes.
First Studied
Drug Approval Stage
How many patients have taken this drug
Meditation Therapy
Quality-of-Life Assessment
Completed Phase 3

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,002 Previous Clinical Trials
1,794,249 Total Patients Enrolled
11 Trials studying Depression
701,339 Patients Enrolled for Depression
National Cancer Institute (NCI)NIH
13,748 Previous Clinical Trials
40,959,371 Total Patients Enrolled
82 Trials studying Depression
66,093 Patients Enrolled for Depression
Gabriel LopezPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
90 Total Patients Enrolled
~7 spots leftby Feb 2026